To address these issues, we hypothesized in this study that CK2 might impact the development of CKD-MBD by modulating RUNX2 and USP7, and we conducted in vivo and in vitro experiments in CKD-MBD mice and pre-osteoblasts to validate this assumption. This evidence concerns the gene RUNX2 and Marchiafava-Bignami disease.